Etern Bio

Etern Biopharma is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of precision oncology therapeutics. The company focuses on the RAS/MAPK signaling pathway, targeting key drivers of cancer growth and resistance such as KRAS, SHP2, and SOS1. Its lead program, ET-001, is a highly selective KRAS G12C inhibitor currently in Phase 1/2 clinical trials for patients with advanced solid tumors. Etern Biopharma utilizes a structure-based drug design platform to develop small molecule inhibitors with optimized pharmacological profiles. The company is backed by prominent investors including Lilly Asia Ventures and Qiming Venture Partners. By addressing difficult-to-drug targets, Etern Biopharma aims to provide transformative treatment options for cancer patients globally.